base metals investing Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
base metals investing Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
base metals investing Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
base metals investing Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
base metals investing Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
base metals investing Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
base metals investing Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research Special Conference on Pancreatic Cancer Research
base metals investing Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
Juggernaut Exploration Announces Bought Deal Private Placement Structured Flow-Through Financing for Gross Proceeds of C$10M
Brunswick Exploration Files Maiden Mineral Resource Estimate NI 43-101 Technical Report for Mirage Project
